AIN457 + AIN457 + AIN457 + Placebo

Phase 3Terminated

0 views this week 0 watching💤 Quiet

Interest: 32/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Uveitis

Conditions

Uveitis

Trial Timeline

Apr 1, 2010 → Oct 1, 2010

NCT ID

NCT01095250

About AIN457 + AIN457 + AIN457 + Placebo

AIN457 + AIN457 + AIN457 + Placebo is a phase 3 stage product being developed by Novartis for Uveitis. The current trial status is terminated. This product is registered under clinical trial identifier NCT01095250. Target conditions include Uveitis.

What happened to similar drugs?

3 of 20 similar drugs in Uveitis were approved

Approved (3) Terminated (8) Active (9)

🔄4 mg CLS-TA Suprachoriodal InjectionClearside BiomedicalPhase 3

🔄Baricitinib + AdalimumabEli LillyPhase 3

✅Ixekizumab Prefilled SyringeEli LillyApproved

🔄adalimumabAbbViePhase 3

🔄Adalimumab + Prednisone + PlaceboAbbViePhase 3

✅AdalimumabAbbVieApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (3)

NCT ID	Phase	Status	Start	Completion	Indication
NCT01103024	Phase 3	Withdrawn	Dec 1, 2010	Feb 1, 2011	Uveitis
NCT01095250	Phase 3	Terminated	Apr 1, 2010	Oct 1, 2010	Uveitis
NCT01032915	Phase 3	Terminated	Feb 1, 2010	Jun 1, 2011	Non-infectious Uveitis

Competing Products

20 competing products in Uveitis

See all competitors

Product	Company	Stage	Hype Score
triamcinolone acetonide (Triesence®)	Clearside Biomedical	Phase 1/2	22
4 mg CLS-TA Suprachoriodal Injection	Clearside Biomedical	Phase 3	30
Baricitinib + Adalimumab	Eli Lilly	Phase 3	44
Ixekizumab Prefilled Syringe	Eli Lilly	Approved	39
adalimumab	AbbVie	Phase 3	40
Adalimumab + Prednisone + Placebo	AbbVie	Phase 3	40
Adalimumab + Prednisone + Placebo	AbbVie	Phase 3	40
Adalimumab	AbbVie	Approved	43
FTY720 + Oral Corticosteroid	Novartis	Phase 2	27
AIN457	Novartis	Phase 3	32
Myfortic	Novartis	Pre-clinical	22
AIN457 + AIN457 + Placebo AIN457	Novartis	Phase 3	32
LFG316 + Conventional Therapy	Novartis	Phase 2	35
Ranibizumab	Novartis	Phase 2	35
AIN457 + Placebo	Novartis	Phase 3	32
AIN457 + AIN457 + AIN457 + Placebo	Novartis	Phase 3	32
AEB071	Novartis	Phase 2	35
AIN457 + AIN457 + AIN457 + Placebo	Novartis	Phase 3	32
Myfortic + Decortin	Novartis	Phase 3	40
AIN457 + AIN 457 + AIN457	Novartis	Phase 2	35